GSK plc GSK announced that the FDA has approved its supplemental new drug application (sNDA) seeking approval for its oral antibiotic Blujepa (gepotidacin) for treating uncomplicated urogenital ...

GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, ...

GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission. Blenrep (belantamab mafodotin) becomes the first ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus ...

Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collection targets using its ...

Harvey Jones has been hunting for the best shares to buy for his SIPP, and found what he thinks is one in a surprising place.

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...

The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in ...

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...